These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 37709296)

  • 21. VSSP abrogates murine ovarian tumor-associated myeloid cell-driven immune suppression and induces M1 polarization in tumor-associated macrophages from ovarian cancer patients.
    Khan ANH; Emmons TR; Magner WJ; Alqassim E; Singel KL; Ricciuti J; Eng KH; Odunsi K; Tomasi TB; Lee K; Abrams SI; Mesa C; Segal BH
    Cancer Immunol Immunother; 2022 Oct; 71(10):2355-2369. PubMed ID: 35166871
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
    Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
    ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer.
    Wan C; Keany MP; Dong H; Al-Alem LF; Pandya UM; Lazo S; Boehnke K; Lynch KN; Xu R; Zarrella DT; Gu S; Cejas P; Lim K; Long HW; Elias KM; Horowitz NS; Feltmate CM; Muto MG; Worley MJ; Berkowitz RS; Matulonis UA; Nucci MR; Crum CP; Rueda BR; Brown M; Liu XS; Hill SJ
    Cancer Res; 2021 Jan; 81(1):158-173. PubMed ID: 33158814
    [TBL] [Abstract][Full Text] [Related]  

  • 24. GATA3 Encapsulated by Tumor-Associated Macrophage-Derived Extracellular Vesicles Promotes Immune Escape and Chemotherapy Resistance of Ovarian Cancer Cells by Upregulating the CD24/Siglec-10 Axis.
    Chen C; Zhang L; Ruan Z
    Mol Pharm; 2023 Feb; 20(2):971-986. PubMed ID: 36547230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy.
    Shen W; Shi P; Dong Q; Zhou X; Chen C; Sui X; Tian W; Zhu X; Wang X; Jin S; Wu Y; Chen G; Qiu L; Zhai W; Gao Y
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.
    Li Y; Shen Z; Chai Z; Zhan Y; Zhang Y; Liu Z; Liu Y; Li Z; Lin M; Zhang Z; Liu W; Guan S; Zhang J; Qian J; Ding Y; Li G; Fang Y; Deng H
    Gut; 2023 Nov; 72(12):2307-2320. PubMed ID: 37507218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunosuppressive M2 TAMs represent a promising target population to enhance phagocytosis of ovarian cancer cells
    Brauneck F; Oliveira-Ferrer L; Muschhammer J; Sturmheit T; Ackermann C; Haag F; Schulze Zur Wiesch J; Ding Y; Qi M; Hell L; Schmalfeldt B; Bokemeyer C; Fiedler W; Wellbrock J
    Front Immunol; 2023; 14():1250258. PubMed ID: 37876933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. C1q
    Zhang S; Peng W; Wang H; Xiang X; Ye L; Wei X; Wang Z; Xue Q; Chen L; Su Y; Zhou Q
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.
    Cao Y; Yu K; Zhang Z; Gu Y; Gu Y; Li W; Zhang W; Shen Z; Xu J; Qin J
    Clin Transl Med; 2024 Feb; 14(2):e1578. PubMed ID: 38356419
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-associated macrophage-derived chemokine CCL5 facilitates the progression and immunosuppressive tumor microenvironment of clear cell renal cell carcinoma.
    Xu W; Wu Y; Liu W; Anwaier A; Tian X; Su J; Huang H; Wei G; Qu Y; Zhang H; Ye D
    Int J Biol Sci; 2022; 18(13):4884-4900. PubMed ID: 35982911
    [No Abstract]   [Full Text] [Related]  

  • 31. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delicaflavone reactivates anti-tumor immune responses by abrogating monocytic myeloid cell-mediated immunosuppression.
    Li L; You W; Wang X; Zou Y; Yao H; Lan H; Lin X; Zhang Q; Chen B
    Phytomedicine; 2023 Jan; 108():154508. PubMed ID: 36332384
    [TBL] [Abstract][Full Text] [Related]  

  • 33. M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer.
    Hensler M; Kasikova L; Fiser K; Rakova J; Skapa P; Laco J; Lanickova T; Pecen L; Truxova I; Vosahlikova S; Moserova I; Praznovec I; Drochytek V; Rehackova M; Brtnicky T; Rob L; Benes V; Pistolic J; Sojka L; Ryska A; Sautes-Fridman C; Fridman WH; Galluzzi L; Spisek R; Fucikova J
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32819974
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Significance of Immunosuppressive Cells as a Target for Immunotherapies in Melanoma and Non-Melanoma Skin Cancers.
    Fujimura T; Aiba S
    Biomolecules; 2020 Jul; 10(8):. PubMed ID: 32707850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. M2 subtype tumor associated macrophages (M2-TAMs) infiltration predicts poor response rate of immune checkpoint inhibitors treatment for prostate cancer.
    JiaWei Z; ChunXia D; CunDong L; Yang L; JianKun Y; HaiFeng D; Cheng Y; ZhiPeng H; HongYi W; DeYing L; ZhiJian L; Xiao X; QiZhao Z; KangYi X; WenBing G; Ming X; JunHao Z; JiMing B; ShanChao Z; MingKun C
    Ann Med; 2021 Dec; 53(1):730-740. PubMed ID: 34032524
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.
    Qi Y; Chang Y; Wang Z; Chen L; Kong Y; Zhang P; Liu Z; Zhou Q; Chen Y; Wang J; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Y; Xu J; Zhang W
    Cancer Immunol Immunother; 2019 Dec; 68(12):2067-2080. PubMed ID: 31720813
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
    El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
    Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Potential crosstalk between SPP1 + TAMs and CD8 + exhausted T cells promotes an immunosuppressive environment in gastric metastatic cancer.
    Du Y; Lin Y; Gan L; Wang S; Chen S; Li C; Hou S; Hu B; Wang B; Ye Y; Shen Z
    J Transl Med; 2024 Feb; 22(1):158. PubMed ID: 38365757
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prognostic Analysis of NSCLC Based on the Tumor-associated Macrophages, Tumor Neo-vessels and PD-L1 Expression in Tumor Microenvironment].
    Hang Q; Ying H; Cheng G; Yang S; Jin J; Chen Y; Chen Q; Jiang Y; Zhao Q; Fang M; Chen M; Lai X
    Zhongguo Fei Ai Za Zhi; 2020 Oct; 23(10):837-844. PubMed ID: 33070512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The immune suppressive factors CD155 and PD-L1 show contrasting expression patterns and immune correlates in ovarian and other cancers.
    Smazynski J; Hamilton PT; Thornton S; Milne K; Wouters MCA; Webb JR; Nelson BH
    Gynecol Oncol; 2020 Jul; 158(1):167-177. PubMed ID: 32446718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.